Mannan-binding lectin may facilitate the clearance of circulating immune complexes - Implications from a study on C2-deficient individuals

Clinical and Experimental Immunology

Volumn 148, Issue 2, 2007, Pages 248-253

  Saevarsdottir, S ^a,b   Steinsson, K ^a   Ludviksson, B R ^a   Grondal, G ^a   Valdimarsson, H ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clearance; Complement C2; Deficiency; Immune complexes; Mannan binding lectin; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MANNAN BINDING LECTIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGEN-ANTIBODY COMPLEX; COMPLEMENT C2; COMPLEMENT PATHWAY, CLASSICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MANNOSE-BINDING LECTIN;

EID: 34247111352     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03349.x     Document Type: Article

References (15)

1. Erlendsson K, Traustadottir K, Freysdottir J, Steinsson K, Jonsdottir I, Valdimarsson H. Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient. Lupus 1993; 2:161-5.
2. Steinsson K, Erlendsson K, Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 1989; 32:906-13.
3. Sjoholm AG, Jonsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol Immunol 2006; 43:78-85.
4. Selander B, Martensson U, Weintraub A et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 2006; 116:1425-34.
5. Saevarsdottir S, Vikingsdottir T, Valdimarsson H. The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scand J Immunol 2004; 60:23-9.
6. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1:237-43.
7. Garred P, Madsen HO, Marquart H et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheumatol 2000; 27:26-34.
8. Royle L, Roos A, Harvey DJ et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003; 278:20140-53.
9. Arnold JN, Wormald MR, Suter DM et al. Human serum IgM glycosylation: identification of glycoforms which can bind to mannan binding lectin. J Biol Chem 2005; 280:29080-7.
10. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002; 1572:401-13.
11. Saevarsdottir S, Kristjansdottir H, Grondal G, Vikingsdottir T, Steinsson K, Valdimarsson H. Mannan binding lectin and complement C4A in Icelandic multicase families with systemic lupus erythematosus. Ann Rheum Dis 2006; 65:1462-7.
12. Lee YH, Witte T, Momot T et al. The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 2006; 52:3966-74.
13. Steffensen R, Hoffmann K, Varming K. Rapid genotyping of MBL2 genemutations using real-time PCR with fluorescent hybridisation probes. J Immunol Meth 2003; 278:191-9.
14. Valdimarsson H, Vikingsdottir T, Bang P et al. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol 2004; 59:97-102.
15. Petersen KA, Matthiesen F, Agger T et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 2006; 26:465-75.